Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BCLS Acquisition Corp.BLSA · Entity 145747 | Director | October 22, 2020 | October 22, 2020 |
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director · See Remarks · 10% owner | February 21, 2025 | February 24, 2025 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Chief Financial Officer | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BCLS Acquisition Corp.
Report date October 22, 2020 · Filed October 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Kalaris Therapeutics, Inc.
Report date February 21, 2025 · Filed February 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,129 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Sale · Disposed 303 · Balance 49,129 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 724,989 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 724,989 F3: Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Scholar Rock Holding Corp
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 619,856 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Sale · Disposed 10,410 · Balance 619,856 F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.
F2: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verona Pharma plc
Report date October 07, 2025 · Filed October 08, 2025
Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2025-10-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-10-07 · Disposition to issuer · Disposed 94,112 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-04-27 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-07 · Disposition to issuer · Disposed 384 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2033-04-27 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-07 · Disposition to issuer · Disposed 96,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-07 · Disposition to issuer · Disposed 240,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2031-08-08 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-10-07 · Disposition to issuer · Disposed 64,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").
F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").
F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 22:09 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 10,410 | $49.57 | $516,070.55 |
DisclosureSEC source: 0001104659-26-045582 · tm2612274-2_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 619,856 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 23:12 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 47,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-013586 · tm266077-7_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,266 F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. F2 · balance_after: Consists of 33,245 shares of common stock, 147,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. Read SEC document |
| January 13, 2026 Filed Jan 16, 2026 00:58 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 16,755 | $42.70 | $715,438.50 |
DisclosureSEC source: 0001104659-26-004224 · tm263352-4_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,245 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units subject to performance-and time-based vesting conditions ("PSUs"). The sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Each PSU represents the contingent right to receive upon vesting of the PSU, one share of the Issuer's common stock. F2 · shares: (continued) The shares vested pursuant to awards that were granted on April 27, 2025. 50,000 shares subject to this PSU vested on January 12, 2026, with an additional 50,000 shares scheduled to vest on April 27, 2027 and the remaining shares vesting in tranches of a combination of performance-based vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four year, provided the Reporting Person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration. F3 · balance_after: 33,245 shares of common stock, 100,000 restricted stock units and 450,000 PSUs. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 64,000 | Not disclosed Strike: $0.78 | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 8 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 64,000 shares Expires 2031-08-08 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 240,000 | Not disclosed Strike: $1.93 | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 7 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 240,000 shares Expires 2034-04-28 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 96,000 | Not disclosed Strike: $2.67 | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 6 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 96,000 shares Expires 2033-04-27 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerShare Options (Right to Buy) · Derivative | 384 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 5 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 384 shares Expires 2032-04-27 F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionRestricted Share Unit · Derivative | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 4 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 72,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4 · derivative.exercise_price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerOrdinary Shares | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · nonDerivative · entry 3 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 72,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Read SEC document |
| October 07, 2025 Filed Oct 8, 2025 20:36 UTC | Verona Pharma plc VRNA · Entity 74409 | Disposition to issuerOrdinary Shares | 94,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · price: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3 · price: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:17 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074382 · tm2522566-2_4seq1.xml · derivative · entry 3 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Ordinary Shares · 24,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F5 · derivative.exercise_price: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:17 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 4,328 | $13.14 | $56,885.93 |
DisclosureSEC source: 0001104659-25-074382 · tm2522566-2_4seq1.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,112 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the Reporting Person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs"). F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of 94,112 Ordinary Shares represented by 11,764 ADSs. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:17 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074382 · tm2522566-2_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:06 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionShare Options (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001104659-25-051986 · tm2515898-2_4seq1.xml · derivative · entry 3 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384 Underlying: Ordinary Shares · 160,000 shares Expires 2032-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:06 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 160,000 | $9.39 | $1,502,928.00 |
DisclosureSEC source: 0001104659-25-051986 · tm2515898-2_4seq1.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,440 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2024. F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $9.375 to $9.4263, inclusive (or $75.00 to $75.41 per ADS, inclusive). The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F4 · balance_after: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:06 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 160,000 | $0.50 | $80,608.00 |
DisclosureSEC source: 0001104659-25-051986 · tm2515898-2_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| May 02, 2025 Filed May 6, 2025 21:01 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 110,067 | $0.00 Strike: $32.91 | $0.00 |
DisclosureSEC source: 0001104659-25-045114 · tm2513936-2_4seq1.xml · derivative · entry 1 Sinha Vikas · CIK 0001337845 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,067 Underlying: Common Stock · 110,067 shares Expires 2035-05-02 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on April 27, 2026, with the remainder vesting in twelve equal quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Read SEC document |
| April 29, 2025 Filed May 2, 2025 00:53 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionShare Options (Right to Buy) · Derivative | 4,952 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · derivative · entry 6 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,048 Underlying: Ordinary Shares · 4,952 shares Expires 2032-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F5 · derivative.exercise_date: The option is fully vested. F4 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 29, 2025 Filed May 2, 2025 00:53 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionShare Options (Right to Buy) · Derivative | 15,048 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · derivative · entry 5 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,952 Underlying: Ordinary Shares · 15,048 shares Expires 2027-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F5 · derivative.exercise_date: The option is fully vested. F4 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 29, 2025 Filed May 2, 2025 00:53 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 4,952 | $8.92 | $44,175.80 |
DisclosureSEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 4 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,440 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price. F3 · balance_after: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs. Read SEC document |
| April 29, 2025 Filed May 2, 2025 00:53 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 4,952 | $0.50 | $2,494.82 |
DisclosureSEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 3 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 29, 2025 Filed May 2, 2025 00:53 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 15,048 | $8.92 | $134,240.20 |
DisclosureSEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,440 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price. Read SEC document |
| April 29, 2025 Filed May 2, 2025 00:53 UTC | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 15,048 | $1.70 | $25,581.60 |
DisclosureSEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionShare Options (Right to Buy) · Derivative | 39,616 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · derivative · entry 6 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,384 Underlying: Ordinary Shares · 39,616 shares Expires 2032-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F5 · security: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F6 · derivative.exercise_date: The option is fully vested. F1 · derivative.underlying_shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. Read SEC document |
| April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionShare Options (Right to Buy) · Derivative | 120,384 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · derivative · entry 5 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 120,384 shares Expires 2027-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F5 · security: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F6 · derivative.exercise_date: The option is fully vested. F1 · derivative.underlying_shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. Read SEC document |
| April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 39,616 | $8.92 | $353,406.41 |
DisclosureSEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 4 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,440 F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer. F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price. F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F4 · balance_after: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs. Read SEC document |
| April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 39,616 | $0.50 | $19,958.54 |
DisclosureSEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 3 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. Read SEC document |
| April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 120,384 | $8.92 | $1,073,921.59 |
DisclosureSEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,440 F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer. F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price. F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. Read SEC document |
| April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment | Verona Pharma plc VRNA · Entity 74409 | Exercise / conversionOrdinary Shares | 120,384 | $1.70 | $204,652.80 |
DisclosureSEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares. Read SEC document |
| April 27, 2025 Filed Apr 29, 2025 22:05 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041454 · tm2513505-4_4seq1.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 F2 · shares: Represents performance based RSUs subject to performance- and time-based vesting conditions (the "PSUs"). The amount reported herein represents the maximum number of shares of the Issuer's common stock that may be issued under this award. The shares subject to this PSU vest in tranches of a combination of performance vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four years, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration. Read SEC document |
| April 27, 2025 Filed Apr 29, 2025 22:05 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041454 · tm2513505-4_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on April 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 21:17 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantRestricted Share Units · Derivative | 96,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041402 · tm2513544-9_4seq1.xml · derivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Ordinary Shares · 96,000 shares Expires not disclosed F1 · security: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.exercise_price: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · shares: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F2 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 303 | $10.08 | $3,052.97 |
DisclosureSEC source: 0000950170-25-025634 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,129 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:11 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 13 | $9.94 | $129.22 |
DisclosureSEC source: 0000950170-25-009197 · ownership.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,432 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:11 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 116 | $9.45 | $1,096.64 |
DisclosureSEC source: 0000950170-25-009197 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,445 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 979 | $0.44 | $430.86 |
DisclosureSEC source: 0000950170-25-004832 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,139,915 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,186 | $0.55 | $1,747.52 |
DisclosureSEC source: 0000950170-24-129259 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,140,894 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,136 | $0.86 | $4,442.13 |
DisclosureSEC source: 0000950170-24-122333 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,080 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,882 | $0.77 | $1,445.00 |
DisclosureSEC source: 0000950170-24-116648 · ownership.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,149,216 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,546 | $0.78 | $1,204.33 |
DisclosureSEC source: 0000950170-24-116648 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,151,098 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 940 | $0.81 | $765.91 |
DisclosureSEC source: 0000950170-24-112914 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,644 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,159 | $0.76 | $2,399.26 |
DisclosureSEC source: 0000950170-24-099103 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,153,584 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,251 | $0.73 | $3,858.43 |
DisclosureSEC source: 0000950170-24-092809 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,156,743 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 20:27 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,858 | $0.74 | $1,373.43 |
DisclosureSEC source: 0000950170-24-085663 · ownership.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161,994 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:27 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,542 | $0.75 | $1,156.65 |
DisclosureSEC source: 0000950170-24-085663 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,163,852 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 20:14 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 939 | $0.72 | $676.08 |
DisclosureSEC source: 0000950170-24-081518 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,165,394 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · balance_after: Includes 36,337 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 28, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,143 | $0.75 | $2,355.05 |
DisclosureSEC source: 0000950170-24-062978 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129,996 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,957 | $0.80 | $3,945.77 |
DisclosureSEC source: 0000950170-24-054511 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,139 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 20:18 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001104659-24-054958 · tm2412993-5_4seq1.xml · derivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Ordinary Shares · 240,000 shares Expires 2034-04-28 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.